Constipation Clinical Trial
— AEGISOfficial title:
Automated Evaluation of Gastrointestinal Symptoms (AEGIS): A Pragmatic Clinical Trial Evaluating the Impact of AEGIS on Clinical Outcomes
Verified date | April 2018 |
Source | Cedars-Sinai Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Healthcare delivery now mandates shorter visits with higher documentation requirements,
undermining the patient-provider interaction. Electronic health records (EHRs) have the
potential to improve outcomes and quality of care in this pressured environment, and are
endorsed by the Patient Protection and Affordable Care Act (ACA) and Health Information
Technology for Economic and Clinical Health (HITECH) Act as an important mechanism to support
value-based healthcare. However, EHR systems were principally designed to support the
transactional needs of administrators and billers, less so to nurture the relationship
between patients and their providers. The purpose of this research is to identify ways to use
EHRs to support clinical gastroenterologists and their patients while meeting the meaningful
use requirements of the HITECH Act.
To improve clinic visit efficiency and meet criteria for meaningful use, investigators
developed a patient-provider portal (P3) that systematically collects patient symptoms using
a computer algorithm called Automated Evaluation of Gastrointestinal Symptoms (AEGIS). AEGIS
utilizes computerized adaptive testing (CAT) to guide patients through questions drawn from a
library of over 300 symptom attributes measuring the timing, severity, frequency, location,
quality, and character of their GI symptoms, along with relevant comorbidities, family
history, and alarm features. The system then automatically "translates" the patient report
into a full narrative HPI available for use by GI providers in an EHR.
In a cross-sectional study in the American Journal of Gastroenterology comparing AEGIS versus
physician-documented HPIs, investigators found that blinded physician reviewers perceived
that AEGIS HPIs were of higher overall quality, better organized, and more succinct,
comprehensible, complete and useful compared to HPIs written by physicians during usual care
in academic GI clinics. In the current study, investigators aim to evaluate
computer-generated HPIs prospectively on a wider scale in diverse academic and
community-based settings. Moreover, investigators aim to test an enhanced AEGIS intervention
that ties patient HPIs to an individualized "education prescription" which guides the patient
through a library of multi-media educational materials on GI symptoms, conditions, and
treatments.
Status | Completed |
Enrollment | 610 |
Est. completion date | February 7, 2018 |
Est. primary completion date | February 7, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Presenting to the gastrointestinal clinic for evaluation. - Able to read and write English. - Has basic computing skills. Exclusion Criteria: - Having been seen and evaluated in the gastrointestinal clinic within the last 8 months. |
Country | Name | City | State |
---|---|---|---|
United States | Cedars-Sinai Medical Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Cedars-Sinai Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of documented alarm symptoms | Prevalence of documented alarm symptoms (blood in the stool, unintentional weight loss, hematochezia, hematemesis) in the clinic note as documented by physicians. | Completed and documented by the physician in the clinic note within 1 week of the initial clinic visit | |
Secondary | Prevalence of diagnosed organic disease | Organic disease (e.g., Celiac disease, inflammatory bowel disease, etc.) diagnosed within 6 months of the initial clinic visit | ||
Secondary | Time to diagnosis of organic disease | Time to diagnosis of organic disease (e.g., Celiac disease, inflammatory bowel disease, etc.) within 6 months of the initial clinic visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Recruiting |
NCT06292949 -
Clinical Study of Resistant Starch in Improving Constipation
|
N/A | |
Recruiting |
NCT04132661 -
MRI Assessment of Mode of Action of Bisacodyl, Single Dose
|
Phase 4 | |
Completed |
NCT02726295 -
The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study
|
Phase 4 | |
Terminated |
NCT02839889 -
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
|
Phase 4 | |
Recruiting |
NCT02255747 -
Anal Dilatation for Infants and Children With Constipation
|
N/A | |
Completed |
NCT02246647 -
Biomarkers for Intestinal Permeability in Patients With Constipation
|
||
Completed |
NCT01566409 -
Maintenance Treatment for Children With Constipation
|
N/A | |
Completed |
NCT01710579 -
Normal Values in Ano-rectal 3D High Resolution Manometry
|
N/A | |
Completed |
NCT02658201 -
Ultrafast MRI Imaging to Exclude Constipation
|
N/A | |
Completed |
NCT02863848 -
Effect of Inulin-type Fructans on Constipated Children.
|
N/A | |
Completed |
NCT01695915 -
Diurnal Variation in Rectal Diameter
|
N/A | |
Completed |
NCT01411501 -
Efficacy and Safety of Acupuncture for Functional Constipation
|
Phase 3 | |
Completed |
NCT01438567 -
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
|
Phase 3 | |
Completed |
NCT01474499 -
A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
|
Phase 3 | |
Completed |
NCT00931853 -
Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).
|
Phase 3 | |
Completed |
NCT01170039 -
The Effectiveness of Lubiprostone in Constipated Diabetics
|
Phase 4 | |
Active, not recruiting |
NCT02442115 -
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
|
||
Completed |
NCT00994851 -
Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.
|
Phase 3 | |
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 |